
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Mumbai, India—The controversy over pharma companies’ incentives to pharmacists in India highlights just how competitive the Indian pharma industry has become.
about 25 years ago
National Crisis Supercedes Coverage Debateabout 25 years ago
PBMs: Merck-Medco in the Hot Seatabout 25 years ago
National Crisis Supercedes Coverage Debateabout 25 years ago
A Five-Year Forecast: Clear Seas Ahead?about 25 years ago
Weak Bones, Strong Marketabout 25 years ago
Approvals: Novartis’ Silver Liningabout 25 years ago
Pfizer and others Pitch Inabout 25 years ago
Oncology: EMEA Approval Lagsabout 25 years ago
Health Plan Premiums: Pharma Takes the Blameabout 25 years ago
Little Elan Becomes a Big Deal





